Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
TARO's Cash-to-Debt is ranked higher than
98% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. TARO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TARO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 2.28 Max: No Debt
Current: No Debt
Equity-to-Asset 0.89
TARO's Equity-to-Asset is ranked higher than
92% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. TARO: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
TARO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.55 Max: 0.89
Current: 0.89
0.23
0.89
Interest Coverage 58.44
TARO's Interest Coverage is ranked lower than
53% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.12 vs. TARO: 58.44 )
Ranked among companies with meaningful Interest Coverage only.
TARO' s Interest Coverage Range Over the Past 10 Years
Min: 2.59  Med: 130.8 Max: 1299.09
Current: 58.44
2.59
1299.09
Piotroski F-Score: 5
Altman Z-Score: 13.60
Beneish M-Score: -0.74
WACC vs ROIC
4.18%
34.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 62.75
TARO's Operating Margin % is ranked higher than
99% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. TARO: 62.75 )
Ranked among companies with meaningful Operating Margin % only.
TARO' s Operating Margin % Range Over the Past 10 Years
Min: -27.89  Med: 31.26 Max: 64.63
Current: 62.75
-27.89
64.63
Net Margin % 51.51
TARO's Net Margin % is ranked higher than
98% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TARO: 51.51 )
Ranked among companies with meaningful Net Margin % only.
TARO' s Net Margin % Range Over the Past 10 Years
Min: -32.77  Med: 34.08 Max: 56.9
Current: 51.51
-32.77
56.9
ROE % 25.64
TARO's ROE % is ranked higher than
88% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. TARO: 25.64 )
Ranked among companies with meaningful ROE % only.
TARO' s ROE % Range Over the Past 10 Years
Min: -92.98  Med: 35.23 Max: 49.88
Current: 25.64
-92.98
49.88
ROA % 22.56
TARO's ROA % is ranked higher than
94% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. TARO: 22.56 )
Ranked among companies with meaningful ROA % only.
TARO' s ROA % Range Over the Past 10 Years
Min: -17  Med: 24.38 Max: 32.05
Current: 22.56
-17
32.05
ROC (Joel Greenblatt) % 52.40
TARO's ROC (Joel Greenblatt) % is ranked higher than
85% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. TARO: 52.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TARO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -30.11  Med: 46.23 Max: 105.96
Current: 52.4
-30.11
105.96
3-Year Revenue Growth Rate 13.90
TARO's 3-Year Revenue Growth Rate is ranked higher than
73% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. TARO: 13.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TARO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.8  Med: 13 Max: 34.7
Current: 13.9
-6.8
34.7
3-Year EBITDA Growth Rate 24.10
TARO's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. TARO: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TARO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24.5  Med: 39.7 Max: 63.7
Current: 24.1
-24.5
63.7
3-Year EPS without NRI Growth Rate 28.30
TARO's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. TARO: 28.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TARO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 38.4 Max: 104.9
Current: 28.3
0
104.9
GuruFocus has detected 3 Warning Signs with Taro Pharmaceutical Industries Ltd $TARO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TARO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TARO Guru Trades in Q1 2016

HOTCHKIS & WILEY 148,983 sh (+8.96%)
Jim Simons 491,300 sh (+8.89%)
David Dreman 172 sh (unchged)
» More
Q2 2016

TARO Guru Trades in Q2 2016

Paul Tudor Jones 2,663 sh (New)
David Dreman 257 sh (+49.42%)
Jim Simons 620,900 sh (+26.38%)
HOTCHKIS & WILEY 151,330 sh (+1.58%)
» More
Q3 2016

TARO Guru Trades in Q3 2016

Paul Tudor Jones 7,636 sh (+186.74%)
David Dreman 414 sh (+61.09%)
Jim Simons 629,900 sh (+1.45%)
HOTCHKIS & WILEY Sold Out
» More
Q4 2016

TARO Guru Trades in Q4 2016

Paul Tudor Jones 14,160 sh (+85.44%)
Jim Simons 547,600 sh (-13.07%)
David Dreman 36 sh (-91.30%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:NYSE:VRX » details
Traded in other countries:TAL.Germany,
Taro Pharmaceutical Industries Ltd is a multinational, science-based pharmaceutical company. It develops manufactures and markets Rx and OTC pharmaceutical products in the United States, Canada and Israel.

Israeli company Taro Pharmaceutical Industries sells generic drugs primarily in the U.S. It produces a significant portion of its own active drug ingredients. Taro in-licensed several branded products from Medicis, which it promotes to U.S. dermatologists and pediatricians through a 60-person salesforce. The firm's experimental treatment for essential tremor, T2000, is approved for a Phase III study in Canada but has yet to receive approval to enter Phase III in the U.S.

Top Ranked Articles about Taro Pharmaceutical Industries Ltd

Gurus' Stocks With Low P/E Ratios Some of the stocks have wide margins of safety
Gurus are buying stocks that are trading with low price-earnings (P/E) ratios. Some are greatly undervalued, according to the DCF calculator. Read more...

Ratios

vs
industry
vs
history
PE Ratio 10.57
TARO's PE Ratio is ranked higher than
90% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.26 vs. TARO: 10.57 )
Ranked among companies with meaningful PE Ratio only.
TARO' s PE Ratio Range Over the Past 10 Years
Min: 3.13  Med: 10.04 Max: 20.41
Current: 10.57
3.13
20.41
PE Ratio without NRI 10.57
TARO's PE Ratio without NRI is ranked higher than
89% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.28 vs. TARO: 10.57 )
Ranked among companies with meaningful PE Ratio without NRI only.
TARO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.84  Med: 10.1 Max: 20.41
Current: 10.57
2.84
20.41
Price-to-Owner-Earnings 11.38
TARO's Price-to-Owner-Earnings is ranked higher than
89% of the 302 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.92 vs. TARO: 11.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TARO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.5  Med: 10.25 Max: 24.34
Current: 11.38
3.5
24.34
PB Ratio 2.53
TARO's PB Ratio is ranked higher than
59% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. TARO: 2.53 )
Ranked among companies with meaningful PB Ratio only.
TARO' s PB Ratio Range Over the Past 10 Years
Min: 1.18  Med: 2.66 Max: 6.4
Current: 2.53
1.18
6.4
PS Ratio 5.44
TARO's PS Ratio is ranked lower than
69% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. TARO: 5.44 )
Ranked among companies with meaningful PS Ratio only.
TARO' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 3.57 Max: 9.71
Current: 5.44
1
9.71
Price-to-Free-Cash-Flow 11.66
TARO's Price-to-Free-Cash-Flow is ranked higher than
80% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.25 vs. TARO: 11.66 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TARO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.87  Med: 11 Max: 28.48
Current: 11.66
5.87
28.48
Price-to-Operating-Cash-Flow 10.86
TARO's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.28 vs. TARO: 10.86 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TARO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.63  Med: 10.33 Max: 26.11
Current: 10.86
5.63
26.11
EV-to-EBIT 7.32
TARO's EV-to-EBIT is ranked higher than
92% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.12 vs. TARO: 7.32 )
Ranked among companies with meaningful EV-to-EBIT only.
TARO' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.5  Med: 7.5 Max: 52.3
Current: 7.32
4.5
52.3
EV-to-EBITDA 7.18
TARO's EV-to-EBITDA is ranked higher than
89% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.99 vs. TARO: 7.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
TARO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 6.6 Max: 52.3
Current: 7.18
4
52.3
PEG Ratio 0.23
TARO's PEG Ratio is ranked higher than
96% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. TARO: 0.23 )
Ranked among companies with meaningful PEG Ratio only.
TARO' s PEG Ratio Range Over the Past 10 Years
Min: 0.23  Med: 0.3 Max: 0.39
Current: 0.23
0.23
0.39
Shiller PE Ratio 21.86
TARO's Shiller PE Ratio is ranked higher than
81% of the 164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.73 vs. TARO: 21.86 )
Ranked among companies with meaningful Shiller PE Ratio only.
TARO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.73  Med: 24.19 Max: 58.09
Current: 21.86
10.73
58.09
Current Ratio 7.44
TARO's Current Ratio is ranked higher than
87% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. TARO: 7.44 )
Ranked among companies with meaningful Current Ratio only.
TARO' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.84 Max: 7.65
Current: 7.44
0.79
7.65
Quick Ratio 6.83
TARO's Quick Ratio is ranked higher than
88% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. TARO: 6.83 )
Ranked among companies with meaningful Quick Ratio only.
TARO' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.97 Max: 7.08
Current: 6.83
0.55
7.08
Days Inventory 266.28
TARO's Days Inventory is ranked lower than
90% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. TARO: 266.28 )
Ranked among companies with meaningful Days Inventory only.
TARO' s Days Inventory Range Over the Past 10 Years
Min: 142.99  Med: 185.96 Max: 278.28
Current: 266.28
142.99
278.28
Days Sales Outstanding 96.88
TARO's Days Sales Outstanding is ranked lower than
64% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. TARO: 96.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
TARO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.09  Med: 68.58 Max: 96.88
Current: 96.88
57.09
96.88
Days Payable 449.72
TARO's Days Payable is ranked higher than
98% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. TARO: 449.72 )
Ranked among companies with meaningful Days Payable only.
TARO' s Days Payable Range Over the Past 10 Years
Min: 38.15  Med: 46.7 Max: 449.72
Current: 449.72
38.15
449.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.50
TARO's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. TARO: 1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TARO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.4  Med: -3.5 Max: 1.5
Current: 1.5
-10.4
1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 16.76
TARO's Price-to-Net-Cash is ranked lower than
61% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.85 vs. TARO: 16.76 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TARO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.83  Med: 15.36 Max: 190.55
Current: 16.76
6.83
190.55
Price-to-Net-Current-Asset-Value 3.31
TARO's Price-to-Net-Current-Asset-Value is ranked higher than
81% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. TARO: 3.31 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TARO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.82  Med: 6.48 Max: 730.33
Current: 3.31
2.82
730.33
Price-to-Tangible-Book 2.54
TARO's Price-to-Tangible-Book is ranked higher than
67% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. TARO: 2.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TARO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 2.43 Max: 15.98
Current: 2.54
0.89
15.98
Price-to-Intrinsic-Value-Projected-FCF 0.81
TARO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
91% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. TARO: 0.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TARO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.8 Max: 23.54
Current: 0.81
0.69
23.54
Price-to-Median-PS-Value 1.53
TARO's Price-to-Median-PS-Value is ranked lower than
69% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. TARO: 1.53 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TARO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.72 Max: 2.47
Current: 1.53
0.1
2.47
Price-to-Peter-Lynch-Fair-Value 0.42
TARO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
95% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. TARO: 0.42 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TARO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.74 Max: 22.71
Current: 0.42
0.13
22.71
Price-to-Graham-Number 1.09
TARO's Price-to-Graham-Number is ranked higher than
83% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.26 vs. TARO: 1.09 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TARO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.41  Med: 1.19 Max: 11.74
Current: 1.09
0.41
11.74
Earnings Yield (Greenblatt) % 13.69
TARO's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. TARO: 13.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TARO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 13.4 Max: 22.4
Current: 13.69
1.9
22.4
Forward Rate of Return (Yacktman) % 32.04
TARO's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.75 vs. TARO: 32.04 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TARO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21.4  Med: 3.8 Max: 53.9
Current: 32.04
-21.4
53.9

More Statistics

Revenue (TTM) (Mil) $948.0
EPS (TTM) $ 11.68
Beta0.32
Short Percentage of Float18.62%
52-Week Range $92.28 - 152.30
Shares Outstanding (Mil)41.03
» More Articles for TARO

Headlines

Articles On GuruFocus.com
Gurus' Stocks With Low P/E Ratios Oct 31 2016 
6 Undervalued Stocks Trading Below the Peter Lynch Value Oct 26 2016 
These Five Stocks Show a Combination of Value and Growth Aug 03 2016 
My Low-Debt List Has Shown a Profit 12 years out of 13 May 13 2016 
These Companies Show High Profit and Low Debt Jun 17 2015 
Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 

More From Other Websites
Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q3, 2017 By the Numbers : February... Feb 13 2017
Taro Pharma 3Q Net $140M Versus $189M Last Year Feb 10 2017
Taro posts 3Q profit Feb 09 2017
Taro posts 3Q profit Feb 09 2017
Taro Provides Results for December 31, 2016 Feb 09 2017
Q3 2017 Taro Pharmaceutical Industries Ltd Earnings Release - After Market Close Feb 09 2017
Taro to Announce Third Quarter Results on February 9, 2017 Jan 31 2017
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA Jan 25 2017
Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : January 13, 2017 Jan 13 2017
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US... Jan 12 2017
TARO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and... Dec 23 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Taro Pharmaceutical Industries Ltd. of... Dec 23 2016
Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopharma plc Dec 23 2016
Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopharma plc Dec 23 2016
GPM Reminds Investors of the December 27th Deadline in the Class Action Lawsuit Against Taro... Dec 20 2016
SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Taro Pharmaceutical Industries... Dec 19 2016
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit... Dec 15 2016
December 27 Deadline Alert: Law Offices of Howard G. Smith Reminds Taro Pharmaceutical Industries... Dec 14 2016
DOJ Files Charges in Generic Drug Price-Fixing Investigation Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)